Search Results
Pembrolizumab plus docetaxel used to treat patients with mCRPC
KEYNOTE-921: pembrolizumab plus docetaxel in chemotherapy-naïve mCRPC
Daniel Petrylak, EMSO 2019 - Phase III KEYNOTE-321 study in prostate cancer
PRINCE: 177Lu-PSMA-617 and pembrolizumab in prostate cancer
ADT Resistant Metastatic Prostate Cancer (mCRPC) - 2021 Prostate Cancer Patient Conference
Prostate Cancer Immunotherapy Trials
Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC
ECHOS: real-world outcomes of docetaxel in patients with mCSPC
Evan Yu, MD, elaborates on the results from KEYNOTE 365 in mCRPC
New treatment possibilities after docetaxel therapy
Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: ASCO 2018 GU Highlights (BMIC-055)
Prostate Cancer Highlights from ESMO 2022
